Please login to the form below

Not currently logged in
Email:
Password:

Boehringer to buy Amgen's California facility

Boehringer Ingelheim is to purchase the rights to all assets at Amgen's development and manufacturing facility in Fremont, California

Boehringer Ingelheim is to purchase the rights to all assets at Amgen's development and manufacturing facility in Fremont, California.

The deal will go through by the end of March, 2011, with Germany-based pharma company Boehringer taking control of the biotech's plant and workforce of 360 employees. The plant was obtained by Amgen following its acquisition of biopharma Abgenix in 2006.

Financial details of Boehringer's takeover were not disclosed.

"With great enthusiasm, we look forward to welcoming the Amgen Fremont employees into the Boehringer Ingelheim family of companies," said Professor Dr Wolfram Carius, Boehringer Ingelheim board of managing directors. "The technological expertise at Fremont and the state-of-the-art facility will enable us to further strengthen our global contract manufacturing business including new biological entity process development and manufacturing efforts."

Boehringer has had a relationship with Amgen for more than 10 years, acting as a contract manufacturer for products developed by Amgen.

Dr Fabrizio Bonanni, executive vice president of operations, Amgen, said: "We look forward to continuing to work closely with [Boehringer] to support Amgen's delivery of safe and effective medicines to patients around the world."

19th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics